Overview

Nivolumab Plus Ipilimumab in Thyroid Cancer

Status:
Active, not recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer. The drugs involved in this study are: - Nivolumab (Opdivo™) - Ipilimumab (Yervoy™)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab